|
[1]MESSINA JP, HUMPHREYS I, FLAXMAN A, et al.Global distribution and prevalence of hepatitis C virus genotypes[J].Hepatology, 2015, 61 (1) :77-87.
|
|
[2]TANG L, MARCELL L, KOTTILIL S.Systemic manifestations of hepatitis C infection[J].Infect Agent Cancer, 2016, 11:29.
|
|
[3]BELOUSOVA V, ABDRABOU AA, MOUSA SA.Recent advances and future directions in the management of hepatitis C infections[J].Pharmacol Ther, 2015, 145:92-102.
|
|
[4]TAMORI A, ENOMOTO M, KAWADA N.Recent advances in antiviral therapy for chronic hepatitis C[J].Mediators Inflamm, 2016, 2016:6841628.
|
|
[5]ELBAZ T, EL-KASSAS M, ESMAT G.New era for management of chronic hepatitis C virus using direct antiviral agents:a review[J].Adv Res, 2015, 6:301-310.
|
|
[6]SORIANO V, LABARGA P, de MENDOZA C, et al.New hepatitis C therapies for special patient populations[J].Expert Opin Pharmaco, 2016, 17 (2) :217-229.
|
|
[7]PASQUINELLI C, MCPHEE F, ELEY T, et al.Single-and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C[J].Antimicrob Agents Chemother, 2012, 56 (4) :1838-1844.
|
|
[8]NAKAMURA M, KANDA T, HAGA Y, et al.Sofosbuvir treatment and hepatitis C virus infection[J].World J Hepatol, 2016, 8 (3) :183-190.
|
|
[9]BHAMIDIMARRI KR, MARTIN P.Finally, safe and effective treatment options for hepatitis C in hemodialysis patients[J].J Hepatol, 2016, 7 (65) :40-47.
|
|
[10]LAGRUTTA A, ZENG H, IMREDY J, et al.Interaction between amiodarone and hepatitis-C virus nucleotide inhibitors in human induced pluripotent stem cell-derived cardiomyocytes and HEK-293 Cav1.2 over-expressing cells[J].Toxicol Appl Pharmacol, 2016, 308:66-76.
|
|
[11]BRAINARD DM, Mc HUTCHISON JG.Bradyarrhythmias associated with sofosbuvir treatment[J].N Engl J Med, 2015, 373:1888.
|
|
[12]MACDONALD A, HARRIS M.Hepatitis C virus NS5A:tales of a promiscuous protein[J].J Gen Virol, 2004 (85) :2485-2502.
|
|
[13]POORDAD F, SCHIFF ER, VIERLING JM, et al.Daclatasvir with sofosbuvir and ribavirin for HCV infection with advanced cirrhosis or post-liver transplant recurrence[J].Hepatology, 2016, 63 (5) :1493-1505.
|
|
[14]JI D, CHEN GF, WANG C, et al.Twelve-week ribavirin-free direct-acting antivirals for treatment-experienced Chinese with HCV genotype 1b infection including cirrhotic patients[J].Hepatol Int, 2016, 10 (5) :798-798.
|
|
[15]AN ZY, SHENG QJ, DING Y, et al.Early efficacy and safety of direct-acting antiviral agents for the treatment of cirrhotic patients with hepatitis C[J].Infect Dis Info, 2016, 29 (2) :81-84, 96. (in Chinese) 安子英, 盛秋菊, 丁洋, 等.直接抗病毒药物治疗丙型肝炎肝硬化早期抗病毒疗效及安全性临床实践研究[J].传染病信息, 2016, 29 (2) :81-84, 96.
|
|
[16]JI F, WANG W, DANG S, et al.Outcomes after sofosbuvir-containing regimens for hepatitis C virus in patients with decompensated cirrhosis:a real-world study[J].Infect Agent Cancer, 2017, 12:48.
|
|
[17]ZHANG XC, LI H, WANG J.Clinical effect of sofosbuvir combined with daclatasvir and ribavirin in treatment of hepatitis C cirrhosis[J].Chin Remed Clin, 2016, 16 (8) :1188-1190. (in Chinese) 张秀春, 李红, 王健.索菲布韦联合达卡他韦及利巴韦林治疗丙型肝炎肝硬化疗效观察[J].中国药物与临床, 2016, 16 (8) :1188-1190.
|
|
[18]ZHONG XQ, CHU XD.Clinical effect of direct-acting antiviral therapy in patients with chronic hepatitis C[J].Med Forums Basic, 2017, 21 (5) :581-582. (in Chinese) 仲小强, 储旭东.慢性丙肝直接抗病毒治疗临床观察[J].基层医学论坛, 2017, 21 (5) :581-582.
|
|
[19]WEI L, ZHANG M, XU M, et al.A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin[J].J Gastroenterol Hepatol, 2016, 31 (11) :1860-1867.
|
|
[20]LIU CH, LIU CJ, SU TH, et al.Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype1b infection in Taiwan[J].J Gastroenterol Hepatol, 2017.[Epub ahead of print]
|
|
[21]WANG BW, KANG W, XIE YM, et al.Clinical effect of 3D regimen (paritaprevir/ritonavir/ombitasvir combined with dasabuvir) in treatment-naive patients with genotype 1 b chronic hepatitis C[J].J Clin Hepatol, 2017, 33 (6) :1092-1095. (in Chinese) 王博文, 康文, 谢玉梅, 等.3D方案 (帕里瑞韦/利托那韦/比他韦联合达塞布韦) 治疗初治基因1b型慢性丙型肝炎患者的效果分析[J].临床肝胆病杂志, 2017, 33 (6) :1092-1095.
|
|
[22]WEI L.Chronic hepatitis C virus infection:current status and transition in China[J].Chin J Intern Med, 2014, 53 (9) :681-684. (in Chinese) 魏来.慢性丙型肝炎病毒感染:中国的现状和转折[J].中华内科杂志, 2014, 53 (9) :681-684.
|
|
[23]CURRY MP, O'LEARY JG, BZOWEJ N, et al.Sofosbuvir and Velpatasvir for HCV in patients with decompensated cirrhosis[J].N Engl J Med, 2015, 373 (27) :2618-2628.
|
|
[24]KWO PY, BADSHAH MB.New hepatitis C virus therapies:drug classes and metabolism, drug interactions relevant in the transplant settings, drug options in decompensated cirrhosis, and drug options in end-stage renal disease[J].Curr Opin Organ Transplant, 2015, 20 (3) :235-241.
|
|
[25]KAWAKAMI Y, IMAMURA M, IKEDA H, et al.Pharmacokinetics, efficacy and safety of daclatasvir plus asunaprevir in dialysis patients with chronic hepatitis C:pilot study[J].J Viral Hepat, 2016, 23 (11) :850-856.
|
DownLoad: